Core Viewpoint - Horizon Technology Finance has significantly reduced its monthly dividend, impacting income investors and raising concerns about its financial health and net asset value (NAV) [2][3]. Dividend Changes - The monthly distribution was cut from $0.11 to $0.06 per share, resulting in an annualized rate of $0.72 per share [3]. - The stock price on March 10, 2026, was $4.29, reflecting a year-to-date decline of 31.37% and a 45.01% drop over the past year [3]. Financial Performance - In 2025, the net investment income (NII) per share was $1.05, which was below the annual distribution of approximately $1.32, indicating that distributions exceeded NII [4]. - The Q4 2025 NII per share was $0.18, aligning with the new monthly rate but indicating very thin coverage [4]. NAV and Credit Quality Concerns - NAV per share decreased from $8.43 at year-end 2024 to $6.98 at year-end 2025, marking a continuous decline over four quarters due to deteriorating credit quality and compressed loan yields [5][6]. - The stock trades at a price-to-book ratio of 0.618, suggesting further deterioration is anticipated [6]. - Four debt investments were rated at the highest risk level, with a fair value of $24.5 million against a cost of $33.8 million, raising additional concerns about credit quality [6].

Core Viewpoint - The article discusses the appeal of business development companies (BDCs) as high-yield investment options compared to traditional dividend stocks, highlighting their requirement to distribute at least 90% of taxable income as dividends [2]. Group 1: Investment Opportunities - BDCs are noted for offering double-digit yields, making them attractive for investors seeking higher returns [2]. - Trinity Capital Inc is identified as a leading BDC, providing funding primarily to technology and life sciences sectors through venture debt and equipment financing [7]. - A recent loan of $35 million to Neuros Medical by Trinity Capital exemplifies its role in supporting growth for private biotech companies [8]. Group 2: Stock Selection Criteria - The selection of stocks was based on a screening process using Barchart's Stock Screener, focusing on high-yielding companies [3][4]. - The analysis included only companies rated "Moderate Buy" to "Strong Buy" by at least 12 analysts, ensuring a broad consensus on the stock ratings [6].

Financial Data and Key Metrics Changes - The company generated net investment income of $42.3 million, or $1.05 per share, on total investment and other income of $90.9 million for the full year [28] - The weighted average annualized portfolio yield on debt investments was 13.7% for the year, down from 15.7% in the prior year, reflecting a lower interest rate environment [28] - Net asset value (NAV) increased year-over-year to $8.73 per share at December 31, 2025, compared to $8.61 per share at December 31, 2024 [31] Business Line Data and Key Metrics Changes - The investment portfolio grew by over $100 million, or 15%, as a result of new fundings exceeding prepayment, repayment, and amortization within the portfolio [19] - The company closed $508 million of new debt commitments to venture growth stage companies, a significant increase from $175 million in 2024 [5] - Fundings for the year reached $287 million, more than double the previous year's $135 million [17] Market Data and Key Metrics Changes - Venture capital deal value increased to $339 billion across more than 16,000 deals as of the end of 2025, marking the second highest in a decade [7] - Deal value in the core venture growth market segment rose 131% year-over-year [7] - The company ended the year with a pipeline exceeding $2 billion, benefiting from increased venture capital investment activity [6] Company Strategy and Development Direction - The company aims to create enduring shareholder value by increasing scale, durability, income-generating assets, and NAV [4] - There is a focus on portfolio diversification, geographic and investment sector rotation, particularly in high-potential sectors leveraging AI [8] - The company is positioning itself to benefit from trends in aerospace, defense, infrastructure, and advanced manufacturing, aligning with national priorities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the venture market's health and signs of liquidity with M&A and IPOs, indicating a well-positioned stance for realizing shareholder value [12] - The company is cautious about macroeconomic impacts but is actively resolving credit situations and making progress [51] - Management believes that the combination of durable AI tailwinds, strong demand, and disciplined underwriting will position the company well for growth in 2026 and beyond [15] Other Important Information - The advisor's income incentive fee waiver has been extended through 2026, and the sponsor purchased more than 1.8 million shares of the company during the third and fourth quarters [15] - The company ended the year with total liquidity of $252.4 million, consisting of cash equivalents and available capacity under the revolving credit facility [34] Q&A Session Summary Question: Is the number of companies raising money this quarter low in historical context? - Management indicated that the low number reflects the freshness of the portfolio vintages and expects fundraising activity to increase in 2026 and 2027 [43] Question: Is there a change in the long-term strategy given the current market conditions? - Management stated that the strategy is refined each year based on market conditions, focusing on strengthening the balance sheet and improving income-earning assets [44][46] Question: Have most negative marks been worked through in the portfolio? - Management expressed that while credit has stabilized, they are still proactive in resolving known situations and making progress [51] Question: What is the visibility on prepayments for the remainder of the quarter? - Management noted that there is currently not much visibility on prepayments for the remainder of the quarter but is monitoring the situation [53] Question: What are the expectations for M&A and IPO activity in 2026? - Management indicated that while IPO optimism may be delayed, M&A activity is picking up, and they remain cautiously optimistic about unique opportunities [62]

Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.18 per share for Q4 2025, down from $0.32 per share in Q3 2025 and $0.27 per share in Q4 2024 [23] - The net asset value (NAV) per share was $6.98 as of December 31, 2025, compared to $7.12 as of September 30, 2025, and $8.43 as of December 31, 2024 [26] - Total investment income for Q4 2025 was $21 million, down from $24 million in the prior year period, primarily due to lower interest income on the debt investment portfolio [22] Business Line Data and Key Metrics Changes - The company achieved a portfolio yield on debt investments of over 14% for Q4 2025 and nearly 16% for the full year 2025, maintaining a position at or near the top of the BDC industry [8] - The debt investment portfolio on a net cost basis stood at $602 million as of December 31, 2025, up 3% from $585 million as of September 30, 2025 [22] - New originations totaled $103 million in Q4 2025, offset by $13 million in scheduled principal payments and $15 million in principal prepayments, refinancings, and partial pay downs [25] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in Q4 2025, with 2025 being the largest year of investment since 2021 at $339 billion [15] - The demand for venture debt capital remains high, and the company expects to be a key supplier of such capital in the coming year and beyond [9] Company Strategy and Development Direction - The company is preparing for a merger with Monroe Capital, which is expected to significantly increase equity capital available for investment and allow for larger venture loans [5][10] - The merger is anticipated to enhance the company's ability to target larger venture loan opportunities for both private and small-cap public companies [18] - The company aims to optimize outcomes with respect to its current portfolio while expanding its venture lending capabilities [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 was a year of transformation, navigating various challenges while laying groundwork for long-term success [4] - The company remains optimistic about the venture lending market, particularly in AI and defense technology sectors, and believes venture debt is a compelling option for companies seeking capital with lower dilution [17] - Management expects to generate NII that covers distributions over time, supported by a strong pipeline of investment opportunities [24] Other Important Information - The company ended the year with a committed and approved backlog of $154 million, up from $119 million at the end of Q3 2025 [13] - The company redeemed its notes due in 2026 with proceeds from the issuance of 7% notes due 2028 [8] Q&A Session Summary Question: Inquiry about the new dividend level decision - Management reviews distribution levels with the board each quarter, considering the current portfolio, run rate, spillover, and growth opportunities to determine a sustainable level [29] Question: Clarification on the percentage at contractual floor - The percentage at contractual floor is 71% [30] Question: Understanding the earnings slide quarter-over-quarter - The lower interest income was primarily driven by lower prepayment activity and the timing of fundings, with significant prepayments occurring in Q3 [35] Question: Opportunities for public company financing - The company offers flexible capital structures that are less dilutive compared to equity, targeting companies that may not be profitable enough to access traditional bank financing [39] Question: Status of non-accrual portfolio companies - The company is working to maximize recoveries from non-accruals, which are at various levels, and has improved the percentage of non-accruals quarter-over-quarter [43] Question: Drivers of realized loss from Tallac Therapeutics - Tallac was a small part of the realized loss, with the overall realized loss being slightly positive for the quarter [48]

Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.18 per share for Q4 2025, down from $0.32 per share in Q3 2025 and $0.27 per share in Q4 2024 [24] - The net asset value (NAV) per share was $6.98 as of December 31, 2025, compared to $7.12 as of September 30, 2025, and $8.43 as of December 31, 2024 [27] - Total investment income for Q4 was $21 million, compared to $24 million in the prior year period, primarily due to lower interest income on the debt investment portfolio [23] Business Line Data and Key Metrics Changes - The current portfolio stood at $647 million, with new originations totaling $103 million in Q4, offset by $13 million in scheduled principal payments and $15 million in principal prepayments [10][26] - The debt portfolio yield was 14.3% for Q4, down from 14.9% in the previous year's Q4, while onboarding yields were 12% for Q4, consistent with historical levels [12][23] - The company ended the year with a committed and approved backlog of $154 million, an increase from $119 million at the end of Q3 [13] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in Q4 2025, with 2025 being the largest year of investment since 2021 [15] - The demand for venture debt capital remains high, and the company expects to be a key supplier of such capital in the coming year [9] Company Strategy and Development Direction - The merger with Monroe Capital is expected to significantly increase equity capital available for investment and allow for larger venture loans [5][7] - The company aims to optimize returns and create future value through collaboration with portfolio companies and a disciplined approach to underwriting new loans [14][19] - The focus remains on targeting larger venture loan opportunities for both private and small-cap public companies post-merger [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but expressed optimism about the groundwork laid for long-term success [4] - The company anticipates that the size of its portfolio and growth expectations will enable it to generate NII that covers distributions over time [25] - The management highlighted the importance of navigating the changing environment, particularly in AI and defense technology sectors [17] Other Important Information - The company redeemed its notes due in 2026 and issued new 7% notes due in 2028 [8] - The company has a strong liquidity position with $189 million in available liquidity as of December 31, 2025 [20] Q&A Session Summary Question: Can you elaborate on the new dividend level decision? - The company reviews distribution levels with the board each quarter, considering the current portfolio, run rate, spillover, and growth opportunities to determine a sustainable level [29][30] Question: What drove the lower interest income? - The lower interest income was primarily due to reduced prepayment activity and the timing of fundings, with significant prepayments occurring in Q3 but only one in Q4 [34][36] Question: What are the opportunities for public company financing? - The company sees opportunities in providing flexible capital structures to companies that may not be profitable and typically resort to equity financing, which is more dilutive [40] Question: Can you provide details on the non-accrual portfolio companies? - The company is working to maximize recoveries on non-accruals, which are at various levels, and has improved the percentage of non-accruals quarter-over-quarter [44][45] Question: What was the driver of the realized loss? - The realized loss included a small position in Tallac Therapeutics, but the overall impact was minimal, with net realized and unrealized results being slightly positive [49][51]

Financial Data and Key Metrics Changes - The merger is expected to provide Horizon with an estimated $165 million of incremental equity capital based on preliminary NAV estimates as of June 30, 2025, enhancing the combined company's estimated NAV to approximately $446 million [6][13]. - The transaction is structured to be accretive to net investment income, with expected G&A savings of approximately $2.5 million, translating to a 30% reduction in operating expenses compared to standalone entities [17]. Business Line Data and Key Metrics Changes - The merger will allow Horizon to leverage the additional capital to provide more investment capital, potentially increasing core net investment income growth [13][14]. - Horizon plans to continue providing venture debt to private companies while also expanding its lending to public small-cap companies, indicating a diversification of its business lines [15][16]. Market Data and Key Metrics Changes - The merger is anticipated to unlock shareholder value, with MRCC shareholders expected to realize a 33% premium to the market trading price as of August 5, 2025 [8][12]. - The combined platform is expected to enhance trading liquidity and provide a larger capital base for larger deals, improving the overall market position of Horizon [14][32]. Company Strategy and Development Direction - The merger is seen as a strategic move to optimize direct lending capabilities and enhance scale, operating efficiencies, and growth potential [5][10]. - Horizon aims to rapidly deploy the proceeds from the merger into attractive portfolio assets while maintaining a focus on operational efficiency and prudent capital deployment [16][17]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the merger will create a better business development company with more capital, scale, and earnings power, ultimately benefiting all shareholders [21][22]. - The management team is aligned with shareholders through fee waivers in the first year, emphasizing a commitment to shareholder success [17]. Other Important Information - The merger is expected to close in December 2025, contingent on regulatory approvals and shareholder votes [10][21]. - The combined board structure post-merger will include independent directors from both companies, ensuring balanced governance [11]. Q&A Session Summary Question: Summary of the transaction steps - The MRCC portfolio will be sold to Monroe's non-traded BDC, with cash proceeds going to Horizon [24]. Question: Nature of the transaction from Horizon's perspective - The transaction is viewed as a cost-efficient equity raise for Horizon [26]. Question: Targets for net investment income yield - No hard targets are set, but the focus will be on running the company efficiently [28]. Question: Timing for capital deployment - Capital is expected to be deployed rapidly, aiming for neutral EPS impact in the first year [29][31]. Question: Impact on deal sizes post-merger - The merger allows for larger deals due to an increased capital base [32]. Question: Lockup for Monroe shareholders - No lockup is contemplated for Monroe shareholders after receiving Horizon shares [40]. Question: G&A expense synergies details - Combined G&A expenses prior to synergies were approximately $8.4 million, expected to reduce to $5.8 million post-merger [41].

Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.27 per share, consistent with the previous quarter but down from $0.38 per share in the same quarter last year [26] - The net asset value (NAV) decreased to $7.57 per share from $8.43 at the end of the previous quarter and $9.64 a year ago, primarily due to fair value adjustments and distributions [27] - Investment income for the first quarter was $25 million, slightly down from $26 million in the prior year period, attributed to lower interest and fee income [24] Business Line Data and Key Metrics Changes - The portfolio at the end of the first quarter stood at $690 million, with new debt investments totaling $100 million and equity investments of $2 million [11] - The debt portfolio yield was 15% for the quarter, compared to 15.6% in the same quarter last year, while onboarding yields were 13%, up from 12.6% in the previous quarter [24][12] - The company funded nine debt investments during the quarter, with a significant portion directed towards life science and technology sectors [11] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in the first quarter, marking a 19% increase from the previous quarter, driven largely by large AI deals [17] - The exit market for VC-backed tech and life science companies remains nearly shut due to tariff-related uncertainties, impacting investor sentiment [18] - The S&P Biotech Select Industry Index is down 14% year over year, reflecting cooling investor sentiment in the life sciences market [18] Company Strategy and Development Direction - The company aims to grow its portfolio while maintaining a focus on high-quality investments, particularly in the tech and life science sectors [10] - The management remains selective in originating loans due to the current macroeconomic environment, with a commitment to optimizing returns from stressed investments [15] - The partnership with Monroe Capital is expected to enhance capital access and operational support, aiding in portfolio growth [9] Management's Comments on Operating Environment and Future Outlook - The management expressed guarded optimism for 2025, despite macroeconomic headwinds impacting recovery from stressed assets [6] - The company anticipates that the venture debt market will remain active, providing opportunities for investment despite current challenges [10] - Management highlighted the importance of maintaining strong liquidity and a robust balance sheet to navigate the current environment [23] Other Important Information - The company declared regular monthly distributions of $0.11 per share through September 2025, supported by undistributed spillover income of $1 per share [7][26] - The company has a committed backlog of $236 million, providing a solid base for future portfolio growth [8] Q&A Session Summary Question: How is the company managing spillover earnings in the current uncertain environment? - The company plans to continue growing distributions through 2025 and will manage spillover earnings quarterly, with confidence in covering distributions over time [32][34] Question: What is the quality of deals currently being pursued? - The company is seeing a higher bar for transaction selection, focusing on companies with strong operational performance and quality VC backing [36][37] Question: Will the company raise leverage ratios to grow the portfolio? - The target leverage ratio is around 1.2x to 1.3x, with the current ratio at 1.29x, indicating a cautious approach to leverage [41] Question: Is there any discussion about cutting the base management fee? - The company’s base management fee is competitive with industry standards, and it is reviewed regularly [43] Question: How does the company plan to address the frozen market conditions? - The company is focusing on generating yield through higher returns from existing portfolio companies rather than relying on warrant expectations [55][52] Question: What is the impact of tariffs on the portfolio? - The primary impact of tariffs is the uncertainty they create, affecting market transactions rather than direct exposure to specific tariffs [63] Question: Has the partnership with Monroe Capital provided additional resources? - The partnership is expected to enhance operational support and focus on stabilizing and growing the business [66]